Systemic low-grade inflammation and hs-CRP: the hidden metabolic killer

High-sensitivity C-reactive protein (hs-CRP) is one of the most important clinical windows into your body’s invisible inflammatory process. Unlike acute inflammation it causes no pain, but it constantly damages the vascular endothelium, blocks insulin receptors and accelerates biological ageing.

What hs-CRP actually measures

hs-CRP is an acute-phase protein made by the liver in response to inflammatory cytokines (mainly IL-6, also TNF-α and IL-1β). The high-sensitivity test measures levels from 0.1 mg/L – far below classic CRP – and can therefore detect the chronic low-grade inflammation typical of metabolic syndrome, atherosclerosis and many degenerative diseases.

In a joint statement of the American Heart Association and the CDC (Pearson et al., Circulation 2003 and later updates), hs-CRP is confirmed as an independent cardiovascular risk marker, to be measured twice 2 weeks apart and the average used – not a single reading during acute illness.

• Optimal: < 1.0 mg/L (low cardiovascular risk)
• Low-to-moderate risk: 1.0–3.0 mg/L
• High cardiovascular risk: > 3.0 mg/L
• > 10 mg/L: usually acute infection – repeat after 2 weeks

The inflammation–insulin-resistance loop

Chronic endothelial inflammation disrupts insulin signalling into the cell, blocking IRS-1 substrate function through serine phosphorylation. Visceral fat behaves as an endocrine organ, continuously releasing inflammatory adipokines (TNF-α, resistin, leptin) and recruiting macrophages that themselves start producing IL-6.

Result: cells become insulin-insensitive before fasting glucose ever rises above 5.6 mmol/L. Hotamisligil’s review (Nature, 2017) calls this state metaflammation – metabolically induced chronic inflammation, the central root of today’s non-communicable diseases.

"Normal blood sugar against high hs-CRP is a warning, not a reassurance – the body is still compensating."

JUPITER and CANTOS: clinical proof

The JUPITER trial (Ridker et al., NEJM 2008) showed that statins reduce cardiovascular events even in people with normal LDL but hs-CRP > 2.0 mg/L – confirming inflammation as an independent driver of atherosclerosis. CANTOS (Ridker et al., NEJM 2017) went further: the specific anti-IL-1β antibody canakinumab reduced recurrent infarction risk independent of LDL change. Inflammation is not a consequence – it is a cause.

Which lifestyle factors lower hs-CRP

• Reducing visceral fat by ≥ 5% of body weight (the strongest single intervention)
• Polyphenol-rich Mediterranean or low-carb diet (PREDIMED, Estruch et al. NEJM 2018)
• Regular strength training 2–3×/week – lowers baseline IL-6
• Aerobic training ≥ 150 min/week
• Quality sleep 7–9 h with a stable circadian rhythm
• Omega-3 (EPA/DHA) ≥ 2 g/day (Calder, Adv Nutr 2017)
• Smoking cessation – lowers hs-CRP by ~30% in 6 months